HRS-4729 Injection for Weight Loss in Adults With Obesity
Tests the injection HRS-4729 against placebo in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07690826, who can take part
Where in China
- Rui Jin Hospital Shanghai Jiao Tong University School of MedicineShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Trial code
- NCT07690826
- Record updated
- 8 July 2026
- Original description
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.Read full original descriptionShow less
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Participants With Obesity
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes. Approximately 252 participants will be enrolled. The primary endpoint is percent change in body weight from baseline at Week 32 versus placebo.
Inclusion: Able and willing to provide a written informed consent; Male or female adults aged 18 to 65 years; BMI: 28.0 to 40.0 kg/m2; Self-reported diet and exercise control for at least 3 months before screening, with body weight change of no more than 5 kg during the previous 3 months.
Exclusion: Prior or planned organ or bone marrow transplantation during the study period; Use of any medication or treatment likely to cause clinically significant weight gain or weight loss within 3 months prior to screening; Participation in any clinical trial of an investigational drug or medical device within 3 months prior to screening; Blood donation or blood loss ≥400 mL, or receipt of a blood transfusion, within 3 months prior to screening; Endocrine disease or history that may have a significant effect on body weight; History of diabetes mellitus (gestational diabetes excepted); Malignancy of any organ system within the past 5 years, irrespective of evidence of local recurrence or metastasis, except for adequately treated localized basal cell carcinoma of the skin, carcinoma in situ of the cervix, and prostate carcinoma in situ; Presence or suspicion of depression, anxiety disorder, bipolar disorder, suicidal ideation, schizophrenia, or other clinically significant psychiatric disorder, or a history of suicide attempt; Known or suspected excessive alcohol use, or a history of alcohol, drug, or substance abuse; Acute or chronic hepatitis, or a history of severe hepatic disease other than metabolic dysfunction-associated fatty liver disease; An autoimmune disease for which systemic corticosteroid or immunosuppressive therapy is planned during the study period; Mental incapacity or language impairment sufficient to preclude adequate understanding of, or participation in, the trial procedures; Any condition that, in the investigator's judgment, would compromise participant safety or otherwise interfere with the assessment of study results; Any hematologic disorder that may interfere with the determination of HbA1c; Investigators, site staff, or other personnel directly involved in conduct of the study, and their immediate family members; employees of the Sponsor.